← Back to Portfolio

Hydra Biosciences

Hydra, a leader in the field of Transient Receptor Potential (TRP) ion channels, has several advanced preclinical assets and one ongoing clinical trial with Boehringher Ingelheim. Hydra's research and development activities focus in the developing treatments for pain, inflammation, anxiety and other diseases using its expertise in novel ion channels. In 2018 Eli Lilly acquired all assets related to Hydra's pre-clinical programme of TRPA1 antagonists that are being studied for the potential treatment of chronic pain syndromes.

LocationCambridge, Massachusetts
CEORussell Herndon
Partner Vincent Miles